Arq 092

Manufactured by Selleck Chemicals

ARQ-092 is a laboratory instrument that measures and analyzes various chemical and physical properties of samples. It is designed to provide accurate and reliable data for research and development purposes.

Automatically generated - may contain errors

Lab products found in correlation

Mk 2206, by Selleck Chemicals (2 mentions) Dithiothreitol (dtt), by Merck Group (1 mentions) Perifosine, by Merck Group (1 mentions) Perifosine, by Adooq (1 mentions) Triciribine, by Selleck Chemicals (1 mentions) At7867, by Selleck Chemicals (1 mentions) Actinomycin d actd, by Merck Group (1 mentions) Mk 2206 2hcl, by Selleck Chemicals (1 mentions) Adult c57bl 6j male mice, by Jackson ImmunoResearch (1 mentions) Cx 4945, by Selleck Chemicals (1 mentions) Roscovitine, by Selleck Chemicals (1 mentions) Celltiter glo assay, by Promega (1 mentions) Wortmannin, by Selleck Chemicals (1 mentions) Capivasertib, by AstraZeneca (1 mentions)

3 protocols using arq 092

Investigating AKT Inhibitors in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

MK-2206 2HCl, triciribine, AT7867, ARQ-092 and CCT1298930 were obtained from Selleckchem (Houston, TX). AKT inhibitor VIII and perifosine were from AdooQ Bioscience (Irvine, CA). The kinase inhibitors were dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, MO), except from perifosine which was dissolved in ethanol. Actinomycin D (ActD) and dithiothreitol (DTT) were from Sigma-Aldrich. Antibodies against LDLR (3839-100) and β-tubulin (T9154-05G) were purchased from BioVision (Milpitas, CA) and Nordic BioSite AB (Täby, Sweden), respectively. Antibodies against AKT1 (2938) and AKT2 (2964) were obtained from Cell Signaling (Danvers, MA). siRNAs against AKT1 (Hs_AKT1_7 FlexiTube siRNA) and AKT2 (Hs_AKT2_5 FlexiTube siRNA) were obtained from Qiagen (Hilden, Germany).

Bjune K., Wierød L, & Naderi S. (2019). Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms. PLoS ONE, 14(6), e0218537.

+ Open protocol

+ Expand

Kinase Inhibitors in Aging Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

All experimental procedures were approved by The Institutional Animal Care and Use Committee (IACUC) of the Cleveland Clinic. The sources of the chemicals for electrophysiology experiments have been described in detail previously^{19 (link)}. Selective kinase inhibitors against CK2 (CX-4945), cyclin-dependent kinase 5 (CDK5, roscovitine), the inactive conformation of AKT (MK-2206), and both active and inactive conformation of AKT (ARQ-092) were purchased from Selleckchem.com (Houston, TX). C57BL/6J adult male mice (young: 2–3 months of age; aging: 12 months of age and 20 months of age) were purchased from Jackson Laboratory (USA) and housed in the Cleveland Clinic animal facility under a 12 hour-light/dark cycle with food and water available ad libitum. Mice expressing neuronal mitochondrial-targeted CFP on a C57BL/6 background (Thy-1 mito-CFP^{30 (link)}) were originally received by the senior author at the University of Washington and were later brought to and bred in the Cleveland Clinic animal facility.

Bastian C., Quinn J., Tripathi A., Aquila D., McCray A., Dutta R., Baltan S, & Brunet S. (2018). CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways. Neurobiology of disease, 126, 47-61.

+ Open protocol

+ Expand

AKT Inhibitor Evaluation in Mutant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Capivasertib was provided by AstraZeneca. MK-2206 and ARQ-092 were purchased from Selleck Chemicals. Compounds were dissolved in DMSO to yield a 10 mM stock, and diluted in assay medium to achieve the desired concentrations. MCF10a cells from stable lines expressing WT or mutant AKT were seeded in 96-well plates and treated with a range of drug concentrations in assay media, and cell viability was assessed 72 h post treatment using the Cell Titer Glo assay (Promega). Viability data were analyzed and IC₅₀ values derived using GraphPad Prism. Wortmannin was purchased from Selleck Chemicals and BYL-719 was kindly provided by the N. Rosen laboratory. MCF10a cells stably expressing AKT1 or AKT2 mutations were seeded in 6-well plates, treated with different concentrations of Wortmannin or BYL-719 in complete growth media, and cell lysates were harvested 2 h post treatment.

Shrestha Bhattarai T., Shamu T., Gorelick A.N., Chang M.T., Chakravarty D., Gavrila E.I., Donoghue M.T., Gao J., Patel S., Gao S.P., Reynolds M.H., Phillips S.M., Soumerai T., Abida W., Hyman D.M., Schram A.M., Solit D.B., Smyth L.M, & Taylor B.S. (2022). AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications, 13, 2111.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!